Nasiri, MJ;
Zangiabadian, M;
Arabpour, E;
Amini, S;
Khalili, F;
Centis, R;
D'Ambrosio, L;
... Sotgiu, G; + view all
(2022)
Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
International Journal of Infectious Diseases
10.1016/j.ijid.2022.02.043.
(In press).
Preview |
Text
1-s2.0-S1201971222001254-main.pdf - Published Version Download (1MB) | Preview |
Abstract
Introduction: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. Methods: We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. Results: After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I2: 95.1%) with no evidence of publication bias (Begg's test; P >0.05). Conclusions: In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.
Type: | Article |
---|---|
Title: | Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis |
Location: | Canada |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.ijid.2022.02.043 |
Publisher version: | https://doi.org/10.1016/j.ijid.2022.02.043 |
Language: | English |
Additional information: | This is an open access article under the CC BY-NC-ND IGO license (http://creativecommons.org/licenses/by-nc-nd/3.0/igo/). |
Keywords: | MDR-TB, TB, bedaquiline, delamanid, effectiveness, safety |
UCL classification: | UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL |
URI: | https://discovery.ucl.ac.uk/id/eprint/10146093 |



1. | ![]() | 6 |
2. | ![]() | 2 |
Archive Staff Only
![]() |
View Item |